Pharmaceutical Quality and Practices

Deviation and OOS Handling in Stability Testing: A GMP-Compliant Approach

Posted on By

Stability testing in pharmaceuticals ensures that drug products maintain their identity, strength, quality, and purity over time. However, deviations and out-of-specification (OOS) results may occur during these studies due to numerous factors such as analytical errors, environmental fluctuations, equipment failure, or genuine product degradation. Prompt and thorough handling of these events is essential to ensure data integrity, regulatory compliance, and ultimately patient safety.
Click to read the full article.

Deviation and OOS Handling in Stability Testing, Pharmaceutical Quality and Practices

Pharmaceutical Quality and Practices: Foundations of GMP and Regulatory Excellence

Posted on By

Quality is the backbone of pharmaceutical manufacturing and regulatory compliance. Ensuring the identity, strength, safety, and efficacy of drug products requires a robust and continuously evolving Quality Management System (QMS). Regulatory agencies such as the FDA, EMA, CDSCO, and WHO mandate the implementation of Good Manufacturing Practices (GMP) and expect pharmaceutical organizations to institutionalize quality as a culture—not merely as a compliance checkbox.
Click to read the full article.

Pharmaceutical Quality and Practices

Good Manufacturing Practices (GMP) for Stability Studies in Pharmaceuticals

Posted on By

Stability Studies are essential for determining the shelf life and storage conditions of pharmaceutical products. These studies must be executed in full compliance with Good Manufacturing Practices (GMP), as required by regulatory authorities such as the FDA, EMA, WHO, and ICH. GMP compliance ensures data integrity, reproducibility, and the reliability of the results used to support product registration, batch release, and post-approval changes.
Click to read the full article.

Good Manufacturing Practices (GMP) for Stability Studies, Pharmaceutical Quality and Practices

Quality by Design (QbD) in Stability Testing: A Lifecycle Approach

Posted on By

Stability testing is a fundamental component of pharmaceutical product development, directly influencing shelf life, packaging decisions, and market access. Traditionally, Stability Studies followed a fixed protocol executed late in the development process. With the introduction of ICH Q8, Q9, and Q10, the concept of Quality by Design (QbD) has transformed stability testing into a science- and risk-based activity integrated across the product lifecycle.
Click to read the full article.

Pharmaceutical Quality and Practices, Quality by Design (QbD) in Stability Testing

Risk-Based Approaches to Stability Testing in Pharmaceuticals

Posted on By

Traditional stability testing in the pharmaceutical industry often follows a uniform approach across all products and markets, regardless of the inherent risk level or regulatory expectations. With increasing product complexity, regulatory scrutiny, and operational demands, there is a growing emphasis on adopting risk-based approaches to optimize stability study design, execution, and lifecycle management.
Click to read the full article.

Pharmaceutical Quality and Practices, Risk-Based Approaches to Stability Testing

Best Practices for Stability Testing Data Integrity in Pharmaceuticals

Posted on By

Stability testing plays a pivotal role in determining the shelf life and regulatory approval of pharmaceutical products. However, the scientific value of these studies hinges on one crucial factor: data integrity. Regulators across the globe—including the FDA, EMA, WHO, and MHRA—have issued serious warnings and even import bans due to compromised data integrity in pharmaceutical stability operations.
Click to read the full article.

Best Practices for Stability Testing Data Integrity, Pharmaceutical Quality and Practices